Abstract:Introduction: The members retinoic acid receptors (RARs) (α, β, and γ) and retinoid X receptors (RXRs) (α, β, and γ) belong to the retinoid receptor family. They regulate the biological action of classical retinoids through nuclear retinoid receptors, a transcription factor that is regulated by ligands. Through the binding of particular retinoic acid-responsive elements (RAREs) located in target gene promoters, RARs and members of the RXRs form heterodimers. By binding to its nuclear receptors and triggering the transcription of the target genes downstream, retinoic acid (RA) mediates the expression of certain genes. Retinoids so mainly control gene expression to carry out their biological actions. RARs are essential for many biological processes, such as development, immunity, reproduction, organogenesis, and homeostasis. Apart from their physiological functions, RARs are also linked to pathologies and tumors due to mutations, protein fusions, changes in expression levels, or abnormal post-translational changes that lead to aberrant functions and homeostasis breakdown. The oncogenic development of animal tissues or cultured cells is linked to altered expression of retinoid receptors. The RAR-α is over-expressed in several malignancies. Increased invasion and migration in several cancer forms, including HNSC carcinoma, pediatric low-grade gliomas, lung adenocarcinoma, and breast cancer, have been linked to its upregulated expression. Numerous approved therapeutic regimens targeting RAR-α have been developed, improving patient survival rates. Objective: This study's main objective was to identify novel RAR-α-targeting drugs and evaluate the expression patterns of RAR-α in breast cancer patients. Methodology: In-silico investigation using a variety of bioinformatics tools like UALCAN, TISCH, TIMER 2.0, ENRICHR, and others were employed to examine the expression of RAR-α. Further we evaluated in-silico inhibition of RAR-α with trifarotene and also tested the cytotoxicity of trifarotene in breast cancer cells. Results: Our research indicates that RAR-α is upregulated in several malignancies including Breast Cancer. It regulates granulocyte differentiation and has an association with the retinoic acid receptor signaling pathway and cellular response to estrogen stimulus. Furthermore, trifarotene was found as a potential synthetic compound that targets RAR-α through in silico and in-vitro study. Discussion: Overall, this research indicates that elevated expression of RAR-α enhances the onset of breast cancer. Using trifarotene medication to target RAR-α will significantly boost the response of breast cancer individuals to treatment and delay the development of resistance to drugs.

Expression of the Retinoic Acid Receptors (rars) and Retinoid X Receptor (rxrs) Genes in Breast Cancer

Expression of Nuclear Retinoid Receptors in Normal, Premalignant and Malignant Gastric Tissues Determined by in Situ Hybridization

Retinoic Acid Nuclear Receptor Α (rarα), a Major Role in Mediating Retinoids Inhibition of Growth in Human Breast Carcinoma Cells

Elevated Expression of Retinoic Acid Receptor-Alpha (rar Alpha) in Estrogen-Receptor-Positive Breast Carcinomas As Detected by Immunohistochemistry

[Retinoic Acid Nuclear Receptor Beta (RAR Beta) Inhibits Breast Carcinoma Growth].

Retinoid-resistant Estrogen Receptor-Negative Human Breast Carcinoma Cells Transfected with Retinoic Acid Receptor-Alpha Acquire Sensitivity to Growth Inhibition by Retinoids.

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference Between Mrna and Protein Expression in Predicting Prognosis of Breast Cancer Patients

Expression of Androgen Receptor in Breast Cancer and Its Prognostic Significance

Bexarotene: a Promising Anticancer Agent

ROR alpha and REV-ERB alpha are Associated With Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer

The potential of retinoic acid receptors as prognostic biomarkers and therapeutic targets in gastric cancer

Exploring the role of trifarotene against RAR-α: an investigation of expression pattern and clinicopathological significance of RAR-α in breast cancer

Expression and significance of RORa and REV-ERBα in human gastric cancer tissues

Expression of Retinoid Acid Receptors in Embryonal Adrenal Gland and Its Relationships to Neuroblastoma

Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Altered RBP1 Gene Expression Impacts Epithelial Cell Retinoic Acid, Proliferation, and Microenvironment

Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression

Combined High Resistin And Egfr Expression Predicts A Poor Prognosis In Breast Cancer

RARRES1 identified by comprehensive bioinformatic analysis and experimental validation as a promising biomarker in Skin Cutaneous Melanoma

Retinoic Acid and Estrogen Modulation of Insulin-like Growth Factor Binding Protein-4 Gene Expression and the Estrogen Receptor Status of Human Breast Carcinoma Cells

Expressions and Functions of Retinoic Acid Receptors Embryonal Adrenal and Neuroblastoma